Stroke Medication: NCS-01
NCS-01, developed by NC Medical Research, is a regenerative medicine for acute strokes that is derived from mesenchymal stem cells (MSC).
MSC is the somatic stem cell that have the differentiation potency to various cells such as osteoblast cells, chondrocyte cells, muscle cells, fat cells, lymphatic systems, and circulatory systems (hearts and blood vessels). The drug has promising application for regeneration of bones, blood vessels, heart muscles, and nervous systems (such as the brain and retina).
A clinical trial phase 1/2 is currently ongoing in the U.S. From 2021 onwards, clinical trials are scheduled to begin in Japan and the U.S.